MeSH Review:
Genital Diseases, Female
- Diagnostic markers of ovarian cancer by high-throughput antigen cloning and detection on arrays. Chatterjee, M., Mohapatra, S., Ionan, A., Bawa, G., Ali-Fehmi, R., Wang, X., Nowak, J., Ye, B., Nahhas, F.A., Lu, K., Witkin, S.S., Fishman, D., Munkarah, A., Morris, R., Levin, N.K., Shirley, N.N., Tromp, G., Abrams, J., Draghici, S., Tainsky, M.A. Cancer Res. (2006)
- Adjuvant tamoxifen in early-stage breast cancer: effects on intercurrent morbidity and mortality. Fornander, T., Rutqvist, L.E., Cedermark, B., Glas, U., Mattsson, A., Skoog, L., Somell, A., Theve, T., Wilking, N., Askergren, J. J. Clin. Oncol. (1991)
- Tumor-associated antigens in cervical cancer tissues and in sera from patients with cervical cancer or with head and neck cancer. Ibrahim, A.N., Robinson, R.A., Marr, L., Abdelal, A.T., Nahmias, A.J. J. Natl. Cancer Inst. (1979)
- Clinical evaluation of circulating serum sialyl Tn antigen levels in patients with epithelial ovarian cancer. Kobayashi, H., Terao, T., Kawashima, Y. J. Clin. Oncol. (1991)
- Stromal cell-derived factor-1alpha (SDF-1alpha/CXCL12) stimulates ovarian cancer cell growth through the EGF receptor transactivation. Porcile, C., Bajetto, A., Barbieri, F., Barbero, S., Bonavia, R., Biglieri, M., Pirani, P., Florio, T., Schettini, G. Exp. Cell Res. (2005)
- Excretion of a tumor-associated trypsin inhibitor (TATI) in urine of patients with gynecological malignancy. Huhtala, M.L., Kahanpää, K., Seppälä, M., Halila, H., Stenman, U.H. Int. J. Cancer (1983)
- Soluble epidermal growth factor receptor (sEGFR) [corrected] and cancer antigen 125 (CA125) as screening and diagnostic tests for epithelial ovarian cancer. Baron, A.T., Boardman, C.H., Lafky, J.M., Rademaker, A., Liu, D., Fishman, D.A., Podratz, K.C., Maihle, N.J. Cancer Epidemiol. Biomarkers Prev. (2005)
- Monthly implant of luteinizing hormone-releasing hormone agonist: a practical therapeutic approach for sex-steroid dependent gynecologic diseases. Lemay, A. Fertil. Steril. (1987)
- Reduction of the stretch modulus of human cervical tissue by prostaglandin E2. Conrad, J.T., Ueland, K. Am. J. Obstet. Gynecol. (1976)
- Plasma dehydroepiandrosterone-to-cortisol ratios as an indicator of stress in gynecologic patients. Ozasa, H., Kita, M., Inoue, T., Mori, T. Gynecol. Oncol. (1990)
- Plasma prostaglandins across the tumor bed of patients with gynecologic malignancy. Mortel, R., Allegra, J.C., Demers, L.M., Harvey, H.A., Trautlein, J., Nahhas, W., White, D., Gillin, M.A., Lipton, A. Cancer (1977)
- Urinary gonadotropin peptide (UGP) as a marker of gynecologic malignancies. Walker, R., Crebbin, V., Stern, J., Scudder, S., Schwartz, P. Anticancer Res. (1994)
- Increased prevalence of luteinizing hormone beta-subunit variant in patients with premature ovarian failure. Takahashi, K., Ozaki, T., Okada, M., Kurioka, H., Kanasaki, H., Miyazaki, K. Fertil. Steril. (1999)
- Serum CA 125 levels in patients with endometriosis: changes in CA 125 levels during menstruation. Masahashi, T., Matsuzawa, K., Ohsawa, M., Narita, O., Asai, T., Ishihara, M. Obstetrics and gynecology. (1988)
- CA 125 in peritoneal fluid: reliable values at high dilutions. Barbati, A., Anceschi, M.M., Di Renzo, G.C., Cosmi, E.V. Obstetrics and gynecology. (1992)
- Evaluation of tumor-associated glycoprotein-72 and CA 125 serum markers in patients with gynecologic diseases. Guadagni, F., Marth, C., Zeimet, A.G., Ferroni, P., Spila, A., Abbolito, R., Roselli, M., Greiner, J.W., Schlom, J. Am. J. Obstet. Gynecol. (1994)
- Carcinoembryonic antigen in patients with gynecologic malignancy. van Nagell, J.R., Meeker, W.R., Parker, J.C., Harralson, J.D. Cancer (1975)
- Serum level of macrophage colony-stimulating factor as a marker for gynecologic malignancies. Suzuki, M., Ohwada, M., Sato, I., Nagatomo, M. Oncology (1995)
- Immunochemical measurement and immunohistochemical detection of membrane-associated placental tissue protein 1. Shirotake, S., Inaba, N., Ohta, Y., Sato, N., Fukazawa, I., Takamizawa, H., Bohn, H. Chem. Pharm. Bull. (1989)
- Conservative management of gynecologic diseases: insulin sensitizing agents in polycystic ovary syndrome. Diamanti-Kandarakis, E., Kandarakis, H.A. Ann. N. Y. Acad. Sci. (2003)